Ligand Pharmaceuticals (LGND) to Release Quarterly Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) is expected to release its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of $1.46 per share and revenue of $55.5890 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Ligand Pharmaceuticals Stock Performance

Ligand Pharmaceuticals stock opened at $189.94 on Thursday. Ligand Pharmaceuticals has a twelve month low of $93.58 and a twelve month high of $212.49. The company has a quick ratio of 24.30, a current ratio of 24.69 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $3.74 billion, a P/E ratio of 91.76 and a beta of 1.14. The stock’s 50 day moving average is $193.91 and its 200 day moving average is $183.36.

Insider Activity at Ligand Pharmaceuticals

In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 1,804 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $188.31, for a total value of $339,711.24. Following the completion of the sale, the chief financial officer owned 26,186 shares of the company’s stock, valued at approximately $4,931,085.66. The trade was a 6.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John W. Kozarich sold 467 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $195.91, for a total value of $91,489.97. Following the transaction, the director directly owned 43,187 shares in the company, valued at $8,460,765.17. The trade was a 1.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,205 shares of company stock valued at $611,192 over the last three months. 7.00% of the stock is owned by corporate insiders.

Institutional Trading of Ligand Pharmaceuticals

A number of hedge funds have recently bought and sold shares of LGND. CIBC Private Wealth Group LLC lifted its holdings in Ligand Pharmaceuticals by 86.3% in the third quarter. CIBC Private Wealth Group LLC now owns 149 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 69 shares during the period. Kestra Advisory Services LLC purchased a new stake in shares of Ligand Pharmaceuticals during the 4th quarter valued at about $31,000. JPL Wealth Management LLC bought a new position in shares of Ligand Pharmaceuticals in the 3rd quarter worth approximately $52,000. Persistent Asset Partners Ltd purchased a new position in shares of Ligand Pharmaceuticals in the fourth quarter worth approximately $150,000. Finally, State of Wyoming bought a new stake in Ligand Pharmaceuticals during the fourth quarter valued at approximately $169,000. Hedge funds and other institutional investors own 91.28% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LGND. Benchmark increased their target price on Ligand Pharmaceuticals from $175.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Oppenheimer upped their price target on shares of Ligand Pharmaceuticals from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, November 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Ligand Pharmaceuticals in a research note on Monday, December 29th. HC Wainwright upped their target price on shares of Ligand Pharmaceuticals from $206.00 to $231.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Stifel Nicolaus increased their price target on shares of Ligand Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Wednesday, December 10th. Six research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $239.33.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.